Castle Biosciences Launches Next-Generation Sequencing Panel for Uveal Melanoma
Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the launch of the DecisionDx®-UMSeq panel that uses next-generation sequencing (NGS) to identify somatic mutations in genes relevant to uveal melanoma (UM). The new test will complement Castle Biosciences’ standard-of-care DecisionDx®-UM gene expression profile (GEP) test that has been shown to be independent of and superior to mutational analysis in assessing likelihood of metastasis in UM.
The GEP test currently provides the best and most well-validated prognostic information about UM tumors. The additive role that the new DecisionDx-UMSeq results may provide in combination with DecisionDx-UM GEP results is undergoing refinement.
For more click here.